Daiichi Sankyo Boosts Oncology Portfolio with Acquisition of Biotech, U3 Pharma
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 96 (Table of Contents)
Published: 21 May-2008
DOI: 10.3833/pdr.v2008.i96.180 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Daiichi Sankyo is to acquire German oncology biotech, U3 Pharma, for €150 M (US$234 M), boosting the Japanese company’s biologics pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS